전체 프로그램

ADC 890 · Antibody 4071 · CGT 2714 · 다음 갱신 D-5 · 마지막 9월 2일

PopularRecently updatedCuratedMost trialsNeeds refreshORRLatestPhase 3FDA approved667 programs
CGTLimited DatastaleNational Cancer Institute (NCI)Phase 2

Anti-hCD70 CAR transduced PBL (Anti-hCD70 CAR transduced PBL)

Pancreatic Cancer; Renal Cell Cancer · Pancreatic Cancer

#PancreaticCancer#CGT#Phase2#cell-gene-therapy#CAR-T+4
Trials 1Status Recruiting
AntibodyLimited DatastaleInstitut BergoniéPhase 2

atezolizumab (Tecentriq, Association atezolizumab + BDB001 + RT)

Solid Tumor, Adult; Pancreatic Cancer · Solid Tumor, Adult

#SolidTumorAdult#Antibody#Phase2#monoclonal-antibody#SolidTumor+3
Trials 1Status Recruiting
AntibodyLimited DatastaleInstitut BergoniéPhase 2

durvalumab (Imfinzi, Association of lurbinectedin and durvalumab)

Small Cell Lung Cancer; Platinum-Sensitive Lung Small Cell Carcinoma · Small Cell Lung Cancer

#SmallCellLungCancer#Antibody#Phase2#monoclonal-antibody#Platinum-SensitiveLungSmallCellC+1
Trials 1Status Discontinued
AntibodyLimited DatastaleRochePhase 2

atezolizumab (Tecentriq, Atezolizumab + Ipatasertib)

Gastric Adenocarcinoma; Metastatic Gastric Cancer · Gastric Adenocarcinoma

#GastricAdenocarcinoma#Antibody#Phase2#monoclonal-antibody#MetastaticGastricCancer+1
Trials 1Status Active
CGTLimited DatastaleRochePhase 1

atezolizumab (Tecentriq, Atezolizumab and Interleukin-12 Gene Therapy)

Non-small Cell Lung Cancer · Non-small Cell Lung Cancer

#Non-smallCellLungCancer#CGT#Phase1#cell-gene-therapy#CAR-T+2
Trials 1Status Discontinued
AntibodyLimited DatastaleRochePhase 2

atezolizumab (Tecentriq, Atezolizumab, 6-mercaptopurine, 6-thioguanine)

Solid Tumor, Adult; Metastatic Cancer · Solid Tumor, Adult

#SolidTumorAdult#Antibody#Phase2#monoclonal-antibody#SolidTumor+3
Trials 1Status Active
CGTLimited DatastaleFred Hutchinson Cancer CenterPhase 1

Autologous Anti-BCMA-CAR-expressing CD4+/CD8+ T-lymphocytes FCARH143 (Autologous Anti-BCMA-CAR-expressing CD4+/CD8+ T-lymphocytes FCARH143)

Recurrent Plasma Cell Myeloma; Refractory Plasma Cell Myeloma · BCMA

#BCMA#CGT#Phase1#cell-gene-therapy#CAR-T+4
Trials 1Status Active
CGTLimited DatastaleRoswell Park Cancer InstitutePhase 1

Autologous Anti-CD83 CAR T-cells (Autologous Anti-CD83 CAR T-cells)

Recurrent Acute Myeloid Leukemia; Refractory Acute Myeloid Leukemia · FRα

#FR#CGT#Phase1#cell-gene-therapy#CAR-T+4
Trials 1Status Recruiting
CGTLimited DatastaleNational Cancer Institute (NCI)Phase 1

Autologous B7-H3 CAR T (Autologous B7-H3 CAR T)

Extensive-Stage Small Cell Lung Cancer; Extrapulmonary Neuroendocrine Carcinoma · FRα

#FR#CGT#Phase1#cell-gene-therapy#CAR-T+4
Trials 1Status Recruiting
CGTLimited DatastaleNational Cancer Institute (NCI)Phase 1

Autologous CCR4 CAR T cells (Autologous CCR4 CAR T cells)

Relapsed and/or Refractory Mature T Cell Malignancy; Peripheral T-Cell Lymphoma · FRα

#FR#CGT#Phase1#cell-gene-therapy#CAR-T+5
Trials 1Status Recruiting
CGTLimited DatastaleNational Cancer Institute (NCI)Phase 2

Autologous HuCD19 (Anti-CD19, Autologous HuCD19, Autologous HuCD19 ( Anti-CD19)CAR T cells)

Leukemia, Lymphocytic, Chronic, B-Cell; B-Lymphocytic Leukemia, Chronic · CD19

#CD19#CGT#Phase2#cell-gene-therapy#CAR-T+5
Trials 1Status Recruiting
CGTLimited DatastaleHebei Senlang Biotechnology Inc…Phase 1

Autologous aPD-L1 armored anti-CD22 CAR T cells (Autologous aPD-L1 armored anti-CD22 CAR T cells)

Solid Tumor, Adult; Cervical Cancer · PD-L1

#PD-L1#CGT#Phase1#cell-gene-therapy#CAR-T+5
Trials 1Status Active
AntibodyLimited DatastaleRochePhase 2

Bevacizumab, RHUMAB VEGF (Avastin, Avastin (Bevacizumab, RHUMAB VEGF))

Rectal Cancer · Rectal Cancer

#RectalCancer#Antibody#Phase2#monoclonal-antibody#Roche
Trials 1Status Active
AntibodyLimited DatastaleRochePhase 1

bevacizumab, reference product (Avastin®, Avastin® (bevacizumab, reference product))

Metastatic Colorectal Cancer (mCRC) · Metastatic Colorectal Cancer (mCRC)

#MetastaticColorectalCancermCRC#Antibody#Phase1#monoclonal-antibody#Roche
Trials 1Status Active
ADCLimited DatastaleFudan UniversityPhase 2

B2: TROP2 ADC with Camrelizumab (B2: TROP2 ADC with Camrelizumab)

Triple-negative Breast Cancer · TROP2

#TROP2#ADC#Phase2#antibody-drug-conjugate#Triple-negativeBreastCancer+1
Trials 1Status Recruiting
CGTLimited DatastaleStanford UniversityPhase 1

B7-H3CART (B7-H3CART)

Ovarian Cancer · B7-H3

#B7-H3#CGT#Phase1#cell-gene-therapy#CAR-T+3
Trials 1Status Recruiting
AntibodyLimited DatastaleSamsung Medical CenterPhase 2

durvalumab (Imfinzi, BAVC-C+Durvalumab)

Cervical Cancer · Cervical Cancer

#CervicalCancer#Antibody#Phase2#monoclonal-antibody#Samsung
Trials 1Status Active
AntibodyLimited DatastaleNavire Pharma Inc., a BridgeBio…Phase 1

nivolumab (Opdivo, BBP-398 with nivolumab)

Non Small Cell Lung Cancer; Solid Tumor · Non Small Cell Lung Cancer

#NonSmallCellLungCancer#Antibody#Phase1#monoclonal-antibody#SolidTumor+1
Trials 1Status Discontinued
AntibodyLimited DatastaleM.D. Anderson Cancer CenterPhase 2

Relatlimab-Nivolumab FDC (BMS-986213, BMS-986213 (Relatlimab-Nivolumab FDC))

Melanoma (Skin) · Melanoma (Skin)

#MelanomaSkin#Antibody#Phase2#monoclonal-antibody#MD
Trials 1Status Recruiting
AntibodyLimited DatastaleBristol-Myers SquibbPhase 3

BMS-986012+Nivolumab (BMS-986489, BMS-986489 (BMS-986012+Nivolumab))

Extensive-Stage Small Cell Lung Cancer · Extensive-Stage Small Cell Lung Cancer

#Extensive-StageSmallCellLungCanc#Antibody#Phase3#monoclonal-antibody#Bristol-Myers
Trials 1Status Recruiting

14 / 34 pages

← PreviousNext →